Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Nov;2(6):672–677. doi: 10.1128/cdli.2.6.672-677.1995

Effects of pretreatment with SDZ MRL 953, a novel immunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs.

H Nakamura 1, A Ishizaka 1, T Urano 1, K Sayama 1, F Sakamaki 1, T Terashima 1, Y Waki 1, K Soejima 1, S Tasaka 1, N Hasegawa 1, et al.
PMCID: PMC170218  PMID: 8574827

Abstract

SDZ MRL 953 (SDZ), a novel immunostimulatory lipid A analog, has been reported to have immunopharmacological activities similar to those of lipopolysaccharide (LPS) but to have little of the toxicity of LPS. We investigated the effects of pretreatment with SDZ on Escherichia coli endotoxin-induced acute lung injury in guinea pigs. Four experimental groups consisted of saline control (n = 16), SDZ (-12 h) plus LPS (2 mg/kg of SDZ per kg of body weight injected intravenously 12 h before intravenous injection of 2 mg of LPS per kg; n = 15), SDZ (-10 min) plus LPS (SDZ injected 10 min before LPS injection; n = 10), and LPS alone (n = 16). The animals were sacrificed, and lung tissue was sampled 4 h after LPS or saline infusion. Lung injury was assessed by measuring the wet weight-to-dry weight ratio and the level of 125I-labeled albumin accumulation in bronchoalveolar lavage fluid relative to that in plasma. In the SDZ (-12 h) plus LPS group, these two parameters of acute lung injury were decreased compared with those in the LPS alone group. However, they were not decreased in the SDZ (-10 min) plus LPS group. We conclude that SDZ attenuates endotoxin-induced acute lung injury when it is administered 12 h before LPS injection. The attenuating effects of SDZ are speculated to be due to down regulation of the response to endotoxin rather than to receptor blocking.

Full Text

The Full Text of this article is available as a PDF (231.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burhop K. E., Proctor R. A., Helgerson R. B., Raetz C. H., Starling J. R., Will J. A. Pulmonary pathophysiological changes in sheep caused by endotoxin precursor, lipid X. J Appl Physiol (1985) 1985 Dec;59(6):1726–1732. doi: 10.1152/jappl.1985.59.6.1726. [DOI] [PubMed] [Google Scholar]
  2. Danner R. L., Eichacker P. Q., Doerfler M. E., Hoffman W. D., Reilly J. M., Wilson J., MacVittie T. J., Stuetz P., Parrillo J. E., Natanson C. Therapeutic trial of lipid X in a canine model of septic shock. J Infect Dis. 1993 Feb;167(2):378–384. doi: 10.1093/infdis/167.2.378. [DOI] [PubMed] [Google Scholar]
  3. Danner R. L., Joiner K. A., Parrillo J. E. Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. J Clin Invest. 1987 Sep;80(3):605–612. doi: 10.1172/JCI113112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Danner R. L., Van Dervort A. L., Doerfler M. E., Stuetz P., Parrillo J. E. Antiendotoxin activity of lipid A analogues: requirements of the chemical structure. Pharm Res. 1990 Mar;7(3):260–263. doi: 10.1023/a:1015874012484. [DOI] [PubMed] [Google Scholar]
  5. Gaultier C., Harf A., Lorino A. M., Atlan G. Lung mechanics in growing guinea pigs. Respir Physiol. 1984 May;56(2):217–228. doi: 10.1016/0034-5687(84)90105-1. [DOI] [PubMed] [Google Scholar]
  6. Golenbock D. T., Ebert S., Will J. A., Proctor R. A. Elimination and tissue distribution of the monosaccharide lipid A precursor, lipid X, in mice and sheep. Antimicrob Agents Chemother. 1988 Jan;32(1):37–41. doi: 10.1128/aac.32.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Golenbock D. T., Will J. A., Raetz C. R., Proctor R. A. Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infect Immun. 1987 Oct;55(10):2471–2476. doi: 10.1128/iai.55.10.2471-2476.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hatherill J. R., Stephens K. E., Nagao K., Ishizaka A., Wilmarth L., Wang J. C., Deinhart T., Larrick J. W., Raffin T. A. Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: chemotaxis, chemiluminescence, and lysosomal enzyme release. J Biol Response Mod. 1989 Dec;8(6):614–624. [PubMed] [Google Scholar]
  9. Hyers T. M., Fowler A. A. Adult respiratory distress syndrome: causes, morbidity, and mortality. Fed Proc. 1986 Jan;45(1):25–29. [PubMed] [Google Scholar]
  10. Ikeda S., Kumazawa Y., Nishimura C., Nakatsuka M., Homma J. Y., Kiso M., Hasegawa A. Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups. Antiviral Res. 1988 Dec 1;10(4-5):167–178. doi: 10.1016/0166-3542(88)90029-0. [DOI] [PubMed] [Google Scholar]
  11. Ikeda S., Tominaga T., Nishimura C., Homma J. Y., Kiso M., Hasegawa A. Antiherpes activity of chemically synthesized lipid A-subunit analogue GLA-60 in immunosuppressed mice. Antiviral Res. 1989 May-Jun;11(4):173–180. doi: 10.1016/0166-3542(89)90002-8. [DOI] [PubMed] [Google Scholar]
  12. Ishizaka A., Hasegawa N., Sakamaki F., Tasaka S., Nakamura H., Kishikawa K., Yamada A., Obata T., Sayama K., Urano T. Effects of ONO-1078, a peptide leukotriene antagonist, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1325–1331. doi: 10.1164/ajrccm.150.5.7952560. [DOI] [PubMed] [Google Scholar]
  13. Kanazawa M., Hasegawa N., Urano T., Sayama K., Tasaka S., Sakamaki F., Nakamura H., Waki Y., Terashima T., Fujishima S. Regional lung hematocrit variation and assessment of acute lung injury. J Appl Physiol (1985) 1994 Aug;77(2):567–573. doi: 10.1152/jappl.1994.77.2.567. [DOI] [PubMed] [Google Scholar]
  14. Lam C., Hildebrandt J., Schütze E., Rosenwirth B., Proctor R. A., Liehl E., Stütz P. Immunostimulatory, but not antiendotoxin, activity of lipid X is due to small amounts of contaminating N,O-acylated disaccharide-1-phosphate: in vitro and in vivo reevaluation of the biological activity of synthetic lipid X. Infect Immun. 1991 Jul;59(7):2351–2358. doi: 10.1128/iai.59.7.2351-2358.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lam C., Schütze E., Hildebrandt J., Aschauer H., Liehl E., Macher I., Stütz P. SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother. 1991 Mar;35(3):500–505. doi: 10.1128/aac.35.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lam C., Schütze E., Liehl E., Stütz P. Effect of SDZ MRL 953 on the survival of mice with advanced sepsis that cannot be cured by antibiotics alone. Antimicrob Agents Chemother. 1991 Mar;35(3):506–511. doi: 10.1128/aac.35.3.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. León P., Redmond H. P., Shou J., Daly J. M. Interleukin 1 and its relationship to endotoxin tolerance. Arch Surg. 1992 Feb;127(2):146–151. doi: 10.1001/archsurg.1992.01420020028004. [DOI] [PubMed] [Google Scholar]
  18. Martin T. R., Pistorese B. P., Chi E. Y., Goodman R. B., Matthay M. A. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest. 1989 Nov;84(5):1609–1619. doi: 10.1172/JCI114338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Opresko L., Wiley H. S., Wallace R. A. Proteins iodinated by the chloramine-T method appear to be degraded at an abnormally rapid rate after endocytosis. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1556–1560. doi: 10.1073/pnas.77.3.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell. 1990 Jul 13;62(1):3–6. doi: 10.1016/0092-8674(90)90230-c. [DOI] [PubMed] [Google Scholar]
  21. Proctor R. A., Will J. A., Burhop K. E., Raetz C. R. Protection of mice against lethal endotoxemia by a lipid A precursor. Infect Immun. 1986 Jun;52(3):905–907. doi: 10.1128/iai.52.3.905-907.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  23. Stevens J. H., O'Hanley P., Shapiro J. M., Mihm F. G., Satoh P. S., Collins J. A., Raffin T. A. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest. 1986 Jun;77(6):1812–1816. doi: 10.1172/JCI112506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Takahashi I., Kotani S., Takada H., Tsujimoto M., Ogawa T., Shiba T., Kusumoto S., Yamamoto M., Hasegawa A., Kiso M. Requirement of a properly acylated beta(1-6)-D-glucosamine disaccharide bisphosphate structure for efficient manifestation of full endotoxic and associated bioactivities of lipid A. Infect Immun. 1987 Jan;55(1):57–68. doi: 10.1128/iai.55.1.57-68.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tate R. M., Repine J. E. Neutrophils and the adult respiratory distress syndrome. Am Rev Respir Dis. 1983 Sep;128(3):552–559. doi: 10.1164/arrd.1983.128.3.552. [DOI] [PubMed] [Google Scholar]
  26. Terashima T., Kanazawa M., Sayama K., Ishizaka A., Urano T., Sakamaki F., Nakamura H., Waki Y., Tasaka S. Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am J Respir Crit Care Med. 1994 May;149(5):1295–1303. doi: 10.1164/ajrccm.149.5.7513596. [DOI] [PubMed] [Google Scholar]
  27. Tuxen D. V., Cade J. F. Effect of aprotinin in adult respiratory distress syndrome. Anaesth Intensive Care. 1986 Nov;14(4):390–399. doi: 10.1177/0310057X8601400411. [DOI] [PubMed] [Google Scholar]
  28. Yonemaru M., Stephens K. E., Ishizaka A., Zheng H., Hogue R. S., Crowley J. J., Hatherill J. R., Raffin T. A. Effects of tumor necrosis factor on PMN chemotaxis, chemiluminescence, and elastase activity. J Lab Clin Med. 1989 Dec;114(6):674–681. [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES